Pliant Therapeutics (PLRX) Interest Expenses (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Interest Expenses of $37.3 million for Q1 2026, up 4558.62% year-over-year from $800000.0 in Q1 2025, and up 1087.29% quarter-over-quarter from $3.1 million in Q4 2025.
Pliant Therapeutics (PLRX) Interest Expenses (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Interest Expenses for 8 consecutive years, with $37.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 4558.62% year-over-year to $37.3 million; the TTM figure through Mar 2026 stood at $37.3 million (up 902.12% YoY), while the FY2025 annual figure was $229.5 million, up 15.64% from the prior year.
- Interest Expenses rose to $37.3 million in Q1 2026 per PLRX's latest filing, from $3.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $40.5 million in Q2 2025 and bottomed at -$1.1 million in Q4 2022.
- Historically, Interest Expenses has averaged $5.1 million across 5 years, with a median of $600000.0 in 2022.
- Annual changes were most pronounced in 2023 — Interest Expenses sank 48.17% — and 2025, when it jumped 4569.82%.
- Pliant Therapeutics' Interest Expenses stood at -$1.1 million in 2022, then jumped by 129.18% to $321000.0 in 2023, then soared by 265.73% to $1.2 million in 2024, then jumped by 167.38% to $3.1 million in 2025, then jumped by 1087.29% to $37.3 million in 2026.
- Business Quant data shows PLRX's Interest Expenses at $37.3 million in Q1 2026, $3.1 million in Q4 2025, and $815000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.27 Mn |
| Mar 31, 2026 | 37.27 Mn |
| Dec 31, 2025 | 3.14 Mn |
| Dec 31, 2025 | 3.14 Mn |
| Sep 30, 2025 | 815,000.00 |
| Sep 30, 2025 | 815,000.00 |
| Jun 30, 2025 | 40.53 Mn |
| Jun 30, 2025 | 40.53 Mn |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 1.17 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 877,000.00 |
| Sep 30, 2024 | 877,000.00 |
| Jun 30, 2024 | 868,000.00 |
| Jun 30, 2024 | 868,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Dec 31, 2023 | 321,000.00 |
| Dec 31, 2023 | 321,000.00 |